BMS-688521

• Description:

  BMS-688521 is a highly potent, orally active inhibitor of the LFA-1/ICAM interaction, with an IC50 of 2.5 nM in the adhesion assay and an IC50 of 60 nM in the MLR assay. BMS-688521 is efficacious in a mouse allergic eosinophilic lung inflammation model[1].

• UNSPSC:

  12352005

• Target:

  Integrin

• Type:

  Reference compound

• Related Pathways:

  Cytoskeleton

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/bms-688521.html

• Concentration:

  10mM

• Purity:

  98.62

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  ClC1=CC(Cl)=CC(N(C(N(C)[C@]23[C@H](C4=CC=C(C#N)C=C4)CN(C5=NC=C(C(O)=O)C=C5)C3)=O)C2=O)=C1

• Molecular Formula:

  C26H19Cl2N5O4

• Molecular Weight:

  536.37

• References & Citations:

  [1]Watterson SH, et al. Small molecule antagonist of leukocyte function associated antigen-1 (LFA-1) : structure-activity relationships leading to the identification of 6- ((5S,9R) -9- (4-cyanophenyl) -3- (3,5-dichlorophenyl) -1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl) nicotinic acid (BMS-688521) . J Med Chem. 2010 May 13;53 (9) :3814-30.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [893397-44-9]